This research study is for people with dementia from Alzheimer's disease who have been experiencing delusions or hallucinations for at least the past 2 months. Qualified study participants must be ages 55 to 95 and have a Care Partner who can help with participation in the study.
In this research study, we are evaluating an investigational drug for the treatment of psychosis symptoms (delusions and/or hallucinations) associated with Alzheimer's disease dementia. "Investigational" means that it has not been approved for use and that its safety and effectiveness are still being studied. Before new medications can be approved for public use, they must be tested in research studies like this one.
After potential participants and their Care Partners have learned about the study and signed an Informed Consent Form confirming this and their willingness to join the study, they will be screened to see if they meet the qualifications to participate. Screening may take up to 49 days.
Study Participants who meet all study requirements will be assigned to one of two doses or a placebo for a period of six weeks. People completing the study may have the option to enroll in a long-term open-label extension study in which all Study Participants will receive the active study drug and will be told at which dose.
Study Participants who do not proceed to the open-label extension study will enter a safety follow-up period of about 30 days after the treatment period ends with about 2 phone calls.
FICTION: Alzheimer’s disease takes away only memories and ability to function.
FACT: The reality is that Alzheimer's-related psychosis symptoms like hallucinations and delusional thinking are very common aspects of the Alzheimer’s journey.
Having dementia can be very difficult—for both those going through it and for their loved ones and Care Partners. When it also includes psychotic episodes, it can be even more unnerving. But dementia-related psychosis symptoms are very common, with more than 2 million people in the U.S. having it, according to the Gerontological Society of America.
Seeing or hearing people or things that are not really there or having strong false beliefs are common but underreported elements of Alzheimer’s disease. While these are among the most distressing symptoms of Alzheimer’s disease, it is important to remember that they happen among Alzheimer's patients often and are a normal and expected aspect of this disease.
A copy of the Data Protection and Privacy Policy for this website is available at this location:
Data Protection and Privacy Policy https://tprausa.com/privacy/